Clinical profile and outcomes in very elderly patients with atrial fibrillation anticoagulated with rivaroxaban: data from the EMIR study.

Autor: Marín, Francisco, Sánchez, Manuel Anguita, Lekuona, Iñaki, Fernández, Marcelo Sanmartín, Barrios, Vivencio, Muñoz, Carlos Perez, Cosín-Sales, Juan, Pérez Cabeza, Alejandro I., Schilling, Vanesa Roldán, Priu, Carles Rafols, Orenes-Piñero, Esteban, Esteve-Pastor, María Asunción

Publikováno v: Journal of Geriatric Cardiology; Jul2024, Vol. 21 Issue 7, p723-732, 10p

Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries

Autor: Francisco Marin, Marcelo Sanmartín Fernández, Iñaki Lekuona, Fernando Arribas, Gonzalo Barón-Esquivias, Vivencio Barrios, Juan Cosin-Sales, Román Freixa-Pamias, Jaime Masjuan, Alejandro I Pérez-Cabeza, Vanessa Roldán Schilling, José Manuel Vázquez Rodríguez, Carles Rafols Priu, Manuel Anguita Sánchez

Publikováno v: Journal of Comparative Effectiveness Research. 11:1173-1184

Objective: To analyze the effectiveness and safety of rivaroxaban in patients with atrial fibrillation (AF). Methods: The clinical profile and outcomes of the EMIR study were indirectly compared with those of ROCKET-AF, eight other Spanish observatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57fa3ee68744398d8d193acaeb1e0851
https://doi.org/10.2217/cer-2022-0111

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study)

Autor: Marcelo Sanmartín Fernández, Francisco Marín, Carles Rafols, Fernando Arribas, Vivencio Barrios, Juan Cosín-Sales, Manuel Anguita Sánchez, Alejandro Pérez Cabeza, Luis Tercedor, Antonio Luis Gamez Lopez, Martín Ruiz, Gustavo Cortez Quiroga, Antonio Luis Arrebola Moreno, Eduardo Sebastian Lopez Sanchez, Javier Torres Llergo, Juan Motero Carrasco, Ignacio Sáinz Hidalgo, Carlos Pérez Muñoz, Adolfo Bolea Lafont, Gonzalo Barón Esquivas, Jose Francisco Monzón, Alfredo Renilla González, Irene Valverde Andre, Tomás Ripoll Vera, Salvador Diez-Aja López, Antonio Melero Pita, Alfonso Macias Gallego, Olga Duran Bobin, Diego Martin Raimondi, Jesus Ignacio Dominguez Calvo, Jose Angel Perez Rivera, Juan R. Costa Vazquez, María Jesús Rollán Gómez, Romà Freixa, Ivo Roca, Lluis Mont Girbau, Ermengol Valles Gros, Nicolás Manito Lorite, David Vilades, Jordi Punti, Axel Sarrias, Marco Paz, Zamira Gomez, Sara Darnes, Juan Manuel Roca Catalán, Javier Pindado Rodriguez, Javier Andrés Novales, Juana Umaran, Ruben Natividad Andres, Esther Recalde Del Vigo, Juan Ramon Beramendi Calero, Laura Quintas, Yolanda Porras Ramos, Ricardo Fernandez Mouzo, Alejandro Rodriguez Vilela, Oscar Díaz Castro, Carlos Gonzalez Juanatey, Julio Martinez Florez, Luis Miguel Rincón Díaz, Juan Manuel Escudier Villa, Esther Merino Lanza, Isabel Antorrena, Rafael Salguero Bodes, Eduardo Alegria, Cristina Llanos Guerrero, Viviana Serra Tomás, Javier Fuertes Beneitez, Jorge Palazuelos Molinero, Roberto Del Castillo, Antonio Alvarez-Vieitez Blanco, Francisco Marin Ortuño, Isabel Ureña, Fernando Olaz Preciado, Ana Peset Cubero, Juan Quiles, Thomas Brouzet, Carlos Israel Chamorro Fernandez, Juan Cosin Sales, Francisco Ridocci Soriano, Enrique Peris Domingo, Belen Puigdueta Vindel, Francisco Javier Parra Jimenez, Gerardo Estruch Catalá, Eduardo Martinez Litago, Virgilio Martinez Mateo, Manuel Royo Gutierrez, Mohaned Monzer Khanjikhatib, Eugenia Vazquez Rey, Javier Elduayen Gragera, Marcos Garcia Aguado, David Cordero Pereda, Patricia Clares Montón, Jose Manuel Vazquez, Iñaki Lekuona

Publikováno v: Journal of Comparative Effectiveness Research. 10:583-593

Aim: To analyze the frequency and variables related to inappropriate rivaroxaban dosage in clinical practice and its impact on outcomes after 2 years. Materials & methods: Postauthorization, observational, multicenter study, in which atrial fibrillat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da00240853a36768589d1a9e2772c4ef
https://doi.org/10.2217/cer-2020-0286

Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study

Autor: Raquel López‐Gálvez, José Miguel Rivera‐Caravaca, Manuel Anguita Sánchez, Marcelo Sanmartín Fernández, Carles Rafols, Alejandro Isidoro Pérez‐Cabeza, Gonzalo Barón Esquivias, Iñaki Lekuona Goya, José Manuel Vázquez Rodríguez, Juan Cosín Sales, Fernando Arribas Ynsaurriaga, Vivencio Barrios, Román Freixa‐Pamias, Francisco Marín

Publikováno v: European Journal of Clinical Investigation. 52

In atrial fibrillation (AF) patients on vitamin K antagonists, a progressive deterioration of renal function is common but there is limited evidence with long-term use of rivaroxaban. Herein, we investigated the change in renal function in AF patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff56eb26f042f947edba40269a9b2b9f
https://doi.org/10.1111/eci.13788